透明质酸酶皮下免疫球蛋白 10%：儿童与成人原发免疫缺陷患者药代动力学比较

时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31

研究问题

However, because of limitations on infusion volumes per infusion site, SCIG requires more frequent dosing (daily to every 2 weeks) than IVIG (every 3–4 weeks) and may require multiple infusion sites [].；Given the potential variation in drug absorption, distribution, and excretion in patients of different ages [, ], it is important to examine whether there are differences in IgG pharmacokinetics (PK) after treatment with fSCIG 10% across age groups and to determine any implications for dosing regimens.；The objective of the current analysis was to compare the PK of IgG in pediatric and adult patients with PID after administration of fSCIG 10% using a large dataset from three prior clinical trials, and to discuss the implications of any potential differences.

方法

Study 1 (; N = 87) was a prospective, open-label, noncontrolled, nonrandomized, multicenter trial in adult and pediatric patients with PID [].；The trial comprised two epochs: in Epoch 1, participants received IVIG 10% for 3 months at 3- or 4-week treatment intervals; in Epoch 2, participants received fSCIG 10% for 14–18 months at 108% of the weekly equivalent Epoch 1 IVIG dose and the same treatment interval.；Study 2 (; N = 66) was a long-term extension of Study 1 in which participants continued fSCIG 10% treatment with the option of switching to a shorter 2-week dosing interval [].；Study 3 (; N = 44) was a prospective, open-label, noncontrolled, multicenter trial in pediatric patients in which fSCIG 10% treatment was initiated with a dose ramp-up (Epoch 1) followed by fSCIG 10% administered at 3- to 4-week treatment intervals for 3 years (Epoch 2) [].

核心结论

Observed differences were not statistically significant, except for mean Ctrough values between adults and pediatric patients aged 2 to <12 years (P < 0.05; ).；There was considerable variability within age groups and between studies, and higher mean and median exposure parameters (Cmax, AUC/week and Cmin) in patients aged 12 to <17 years in Study 1 versus the same age group in Study 3 were reported.；This could be at least partially attributed to the higher dose of fSCIG 10% in Study 1 when 108% dosing conversion was used for patients switching from IVIG to fSCIG 10%. ‖ 结论：These results indicate that age-based dose adjustments are not warranted; rather, dosing should be guided by the physician’s clinical judgment, informed by the patient’s IgG trough levels and individual therapeutic needs.

局限

However, a limitation of conventional SCIG is the limited volume of IgG that can be administered at a single site or a single infusion, necessitating more frequent infusions than IVIG []. fSCIG overcomes this limitation by enabling higher volumes to be administered in a single infusion, thereby combining the benefits of both IVIG and conventional SCIG [, , , ].；Relatively small sample sizes are a common limitation of PK analyses of pediatric patient data from clinical trials due to the difficulties with the number and volume of blood samples that can be obtained from children [].；These results indicate that age-based dose adjustments are not warranted; rather, dosing should be guided by the

对本项目的价值

★☆☆☆☆ 干预证据决定参照标准效应量——任何抗衰干预的收益至少应对标该基线。设计 phase 3。

全文来源

PMC JATS 全文（正文 17,284 字符，已过标题/DOI 逐字归属校验）

原文题录

• 英文标题：Comparison of hyaluronidase-facilitated subcutaneous immunoglobulin 10% pharmacokinetics in pediatric and adult patients with primary immunodeficiency: an analysis of three phase 3 clinical trials.
• 期刊与标识：Immunother Adv · PMID 42960290 · DOI 10.1093/immadv/ltag022